Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 01 Jun 2016 New trial record